SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: john.d who wrote (6901)3/7/2001 9:03:04 PM
From: Mark Bartlett  Read Replies (2) | Respond to of 14101
 
john,

<<I suspect it might be the part were Kuhne mentions that they are going to show the unblinded results to the FDA.>>

Maybe I am the one blinded, but the only reference I see, regarding showing the FDA any data is:

A blinded interim analysis of this trial will be conducted soon and presented to the FDA

Is there something I missed, because the copy I have says BLINDED? I am not trying to be funny here, I really am asking if I missed something in the PR.

Assuming I did not, showing the FDA a blinded interim study would, IMO, only be done if there were two very clear and distinct groups emerging in the trial. I personally believe that to be the case.

If I missed something, please let me know.

Best to all,

Mark



To: john.d who wrote (6901)3/8/2001 1:00:00 AM
From: Joe Krupa  Read Replies (1) | Respond to of 14101
 
Hi John,

Personally, I don't see that reference to the FDA as being too sensitive. Who knows what is going on behind the scenes right now though?

I noticed that release can still be found when searching the web:

oxochemie.com

They've just taken away the link to it.

joe


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News